A Study of the Effects of Aging on Bone Formation in Men

Overview

Información sobre este estudio

The purpose of this study is to identify new mechanisms responsible for age related impairment in bone formation by studying specific genes and pathways related to bone formation.  

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria

  • Normal men
  • Young, aged 25-40 years
  • Old, aged 60-80 years

Exclusion Criteria

  • Abnormality in any of the screening laboratory studies 
    • If found to have low body stores of vitamin D (serum 25-hydroxyvitamin D of < 20 ng/ml), subjects will be treated with 1000 IU/day of vitamin D for 8 weeks and then rechecked
      • If the level is still < 20 ng/ml, they will receive a second 8 week course of vitamin D
      • If, following that, the level is still < 20 ng/ml, they will not continue in the study and will be referred to their primary physician for further evaluation
  • Presence of significant liver or renal disease
  • Malignancy (including multiple myeloma)
  • Malabsorption
  • Diabetes
  • Hypoparathyroidism
  • Hyperparathyroidism
  • Acromegaly
  • Cushing’s syndrome
  • Hypopituitarism
  • Severe chronic obstructive pulmonary disease
  • Treatment with any of the following drugs
    • Adrenocorticosteroids (> 3 months at any time or > 10 days within the previous year)
    • Anticonvulsant therapy (within the previous year)
    • Pharmacological doses of thyroid hormone (causing decline of thyroid stimulating hormone below normal)
    • Calcium supplementation of > 1200 mg/d (within the preceding 3 months)
    • Testosterone therapy
    • Teriparatide (within the past year)
    • Bisphosphonates within the past 3 years
  • A clinical history of osteoporotic fracture (vertebral, hip, or distal forearm) 
  • To avoid confounding by hypogonadism, particularly in the elderly males, we will obtain free testosterone levels in all subjects and exclude those with levels < 9 ng/dL (the lower limit of normal in our laboratory)

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Sundeep Khosla, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20271269

Mayo Clinic Footer